🩸That's a wrap for #ISLB2026! 🧬
Lots of science, new technological developments, and the best networking in Madrid.
From plenary sessions to fun photocalls, this is what community looks like! 📸
See you next year in Bologna
@isliquidbiopsy @ExcelenciaOnco1 @UmbertoMalapel1
Lots of science, new technological developments, and the best networking in Madrid.
From plenary sessions to fun photocalls, this is what community looks like! 📸
See you next year in Bologna
@isliquidbiopsy @ExcelenciaOnco1 @UmbertoMalapel1
1
5
10
437
Full house at #ISLB2026! 2nd day 🩸
Standing room only —> everyone wants to hear the latest in liquid biopsy. 🧬
@isliquidbiopsy @UmbertoMalapel1 @ErulEnes @MJOSESERRANO19
Standing room only —> everyone wants to hear the latest in liquid biopsy. 🧬
@isliquidbiopsy @UmbertoMalapel1 @ErulEnes @MJOSESERRANO19
0
7
10
372
ELO retweeted
Stop by the poster area at #ISLB2026! Meet the researchers, ask questions and explore the science together.
#LiquidBiopsy @UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @DrYukselUrun @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez androRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @BrunaPellini @LuisRaezMD
#LiquidBiopsy @UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @DrYukselUrun @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez androRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @BrunaPellini @LuisRaezMD
1
8
10
478
ELO retweeted
#ISLB2026 | Dr. @KonVenetis
Case-based Molecular Testing in Breast Cancer
Key highlights:
• Tissue–plasma ESR1 discordance can reflect tumour heterogeneity and treatment-driven clonal evolution.
• Plasma testing may reveal resistant clones missed by a single-site biopsy.
• y part of the decision: prior treatments and trial eligibility determine how well the evidence fits the patient.
#LiquidBiopsy #BreastCancer #ESR1
#LiquidBiopsy @UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @DrYukselUrun @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez @PasqualePisapia @Al3ssandroRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @BrunaPellini @LuisRaezMD
Case-based Molecular Testing in Breast Cancer
Key highlights:
• Tissue–plasma ESR1 discordance can reflect tumour heterogeneity and treatment-driven clonal evolution.
• Plasma testing may reveal resistant clones missed by a single-site biopsy.
• y part of the decision: prior treatments and trial eligibility determine how well the evidence fits the patient.
#LiquidBiopsy #BreastCancer #ESR1
#LiquidBiopsy @UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @DrYukselUrun @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez @PasqualePisapia @Al3ssandroRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @BrunaPellini @LuisRaezMD
0
8
12
521
Even during the breaks at #ISLB2026, there's always time for a fun photocall! 📸
So proud to be here in Madrid with my Molecular Oncology Lab team from @eom.
Great science, great teamwork 🩸🩸 @eOM_Valencia @fihguv @isliquidbiopsy
So proud to be here in Madrid with my Molecular Oncology Lab team from @eom.
Great science, great teamwork 🩸🩸 @eOM_Valencia @fihguv @isliquidbiopsy
0
4
16
265
✨Made it! Ready to kick off #ISLB in Madrid 🇪🇸
Let the liquid biopsy talks begin! 🧬
@isliquidbiopsy @UmbertoMalapel1 @drgandara @MJOSESERRANO19
Let the liquid biopsy talks begin! 🧬
@isliquidbiopsy @UmbertoMalapel1 @drgandara @MJOSESERRANO19
0
5
9
252
ELO retweeted
🗣️ El cáncer de pulmón también es investigación, avances y nuevas oportunidades.
⭕¿Y si cambiamos la pregunta?
👉 Nuestros especialistas ponen el foco en los retos científicos y sanitarios que pueden cambiar su futuro.
🙌 Es hora de hablar de lo que realmente importa.
mosLaPregunta #DíaMundialDelCáncerDePulmón
⭕¿Y si cambiamos la pregunta?
👉 Nuestros especialistas ponen el foco en los retos científicos y sanitarios que pueden cambiar su futuro.
🙌 Es hora de hablar de lo que realmente importa.
mosLaPregunta #DíaMundialDelCáncerDePulmón
0
3
5
280
Packed and ready! 🧳
On my way to Madrid for the ISLB Congress!
So excited to reconnect with the liquid biopsy community, share what we've been working on, and learn from everyone there.
See you soon, Madrid! 🇪🇸 #LiquidBiopsy @isliquidbiopsy @ExcelenciaOnco1 @UmbertoMalapel1
On my way to Madrid for the ISLB Congress!
So excited to reconnect with the liquid biopsy community, share what we've been working on, and learn from everyone there.
See you soon, Madrid! 🇪🇸 #LiquidBiopsy @isliquidbiopsy @ExcelenciaOnco1 @UmbertoMalapel1
0
3
10
216
ELO retweeted
🏥El @HGUVALENCIA pone en marcha #ERASTOR, un programa para mejorar la recuperación de los pacientes sometidos a cirugía torácica
🫁 Optimiza todo el proceso asistencial: desde la preparación del paciente antes de la operación hasta su recuperación
📎 breu.gva.es/b/9uP6np
🫁 Optimiza todo el proceso asistencial: desde la preparación del paciente antes de la operación hasta su recuperación
📎 breu.gva.es/b/9uP6np
0
6
9
916
ELO retweeted
See You in Madrid for ISLB 2026!
The countdown is almost over! From 7–9 November 2026, the global liquid biopsy community will come together in Madrid, Spain, for the ISLB 2026 Annual Congress.
This year marks a special milestone as we celebrate 10 years of ISLB, bringing chers, clinicians, and industry experts to share groundbreaking discoveries, exchange knowledge, and shape the future of liquid biopsy.
We look forward to welcoming you for three days of scientific innovation, meaningful discussions, and valuable connections.
✈️ Safe travels to everyone joining us. See you in Madrid!
#ISLB2026 #LiquidBiopsy #ISLB10Years #CancerResearch #PrecisionMedicine #Madrid2026
The countdown is almost over! From 7–9 November 2026, the global liquid biopsy community will come together in Madrid, Spain, for the ISLB 2026 Annual Congress.
This year marks a special milestone as we celebrate 10 years of ISLB, bringing chers, clinicians, and industry experts to share groundbreaking discoveries, exchange knowledge, and shape the future of liquid biopsy.
We look forward to welcoming you for three days of scientific innovation, meaningful discussions, and valuable connections.
✈️ Safe travels to everyone joining us. See you in Madrid!
#ISLB2026 #LiquidBiopsy #ISLB10Years #CancerResearch #PrecisionMedicine #Madrid2026
0
6
8
286
ELO retweeted
Looking forward to #ISLB2026 in Madrid next week!
Excited to discuss 🩸🧬liquid biopsy in bladder cancer and learn from colleagues across oncology.
How close are we to turning promising biomarkers into better patient care? @OncoAlert @OpenMedicineHQ @ChristianRolfo @UmbertoMalapel1 @ElJanLe @tompowles1 @Uromigos
Excited to discuss 🩸🧬liquid biopsy in bladder cancer and learn from colleagues across oncology.
How close are we to turning promising biomarkers into better patient care? @OncoAlert @OpenMedicineHQ @ChristianRolfo @UmbertoMalapel1 @ElJanLe @tompowles1 @Uromigos
Dive into the latest applications of liquid biopsy across a diverse range of cancers at the Tumor Type Related session during the 8th Annual Congress of the International Society of Liquid Biopsy (ISLB 2026).
Bringing together leading experts from across the field, this session cific advances and perspectives shaping the use of liquid biopsy in oncology.
Chaired by Dr Natasha Leighl and Prof. Nicola Fusco, the session will feature:
• Dr Adela Cañete – Paediatrics SNC Tumors & Liquid Biopsy
• Professor Yüksel Ürün – Liquid Biopsy in Bladder Cancer
• Dr Scott Bratman – Multimodal Assays in HN/Perspectives from Radiation Oncology
• Dr Ann Kathrin Eisfeld – MRD and Hematologic Malignancies
• Dr Joan Anton Puig-Butillé – Melanoma and Liquid Biopsy Including Fragmentomics
• Dr Sadakatsu Ikeda – Updates in GI Cancers Beyond Colorectal
Join us in Madrid to hear tumour-specific perspectives on how liquid biopsy is being applied across oncology and where the field is heading next.
📅 7–9 November 2026
📍 Meliá Castilla, Madrid, Spain
Explore the scientific program and register: islb-congress.info
#ISLB2026 #LiquidBiopsy #Oncology #CancerResearch #PrecisionOncology
0
7
12
916
Attending ESMO2026! Visit us at booth S1038. @eOM_Valencia @MJOSESERRANO19 @ChristianRolfo @isliquidbiopsy 🩸🩸
0
2
7
344
ELO retweeted
See which technologies are shaping the next generation of liquid biopsy at ISLB 2026.
The technical session “Evolving and Future Methodologies in Liquid Biopsy: CTCs, Tumor Vesicles and Emerging Approaches” will spotlight innovative methods expanding what can be detected, stood through liquid biopsy.
Topics will include:
• Extracellular vesicles as functional biomarkers
• Microfluidic isolation and functional analysis of circulating tumour cells
• Multimodal liquid biopsy in small cell lung cancer
• Diagnostic leukapheresis and molecular characterisation of CTCs
• Multi-omic approaches to blood-based cancer biomarkers
Chaired by Dr María José Serrano and Prof Paola Gazzaniga, the session will feature contributions from:
• Dr Kenneth Witwer
• Assoc. Prof. Han Wei Hou
• Dr Alfonso Calvo
• Prof Nikolas Stoecklein
• Prof Megan Hitchins
• Dr Mattia Boeri
Join us in Madrid on Saturday, 7 November, as researchers explore the technologies and emerging approaches helping define the future of liquid biopsy.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 → islb-congress.info
#ISLB2026 #LiquidBiopsy #CTCs #ExtracellularVesicles #CancerResearch #PrecisionOncology
The technical session “Evolving and Future Methodologies in Liquid Biopsy: CTCs, Tumor Vesicles and Emerging Approaches” will spotlight innovative methods expanding what can be detected, stood through liquid biopsy.
Topics will include:
• Extracellular vesicles as functional biomarkers
• Microfluidic isolation and functional analysis of circulating tumour cells
• Multimodal liquid biopsy in small cell lung cancer
• Diagnostic leukapheresis and molecular characterisation of CTCs
• Multi-omic approaches to blood-based cancer biomarkers
Chaired by Dr María José Serrano and Prof Paola Gazzaniga, the session will feature contributions from:
• Dr Kenneth Witwer
• Assoc. Prof. Han Wei Hou
• Dr Alfonso Calvo
• Prof Nikolas Stoecklein
• Prof Megan Hitchins
• Dr Mattia Boeri
Join us in Madrid on Saturday, 7 November, as researchers explore the technologies and emerging approaches helping define the future of liquid biopsy.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 → islb-congress.info
#ISLB2026 #LiquidBiopsy #CTCs #ExtracellularVesicles #CancerResearch #PrecisionOncology
0
8
9
476
ELO retweeted
Advancing liquid biopsy requires more than promising technology — it requires collaboration, robust evidence and meaningful exchange between research and clinical practice.
Researchers, clinicians and industry experts will come together in Madrid to examine the latest evidence, explore how liquid biopsy can continue to support more informed approaches to cancer care.
Be part of the discussions shaping the next chapter of liquid biopsy.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 → islb-congress.info
#ISLB2026 #LiquidBiopsy #PrecisionOncology #CancerResearch #Oncology #CancerCare
Researchers, clinicians and industry experts will come together in Madrid to examine the latest evidence, explore how liquid biopsy can continue to support more informed approaches to cancer care.
Be part of the discussions shaping the next chapter of liquid biopsy.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 → islb-congress.info
#ISLB2026 #LiquidBiopsy #PrecisionOncology #CancerResearch #Oncology #CancerCare
1
6
10
455
ELO retweeted
🧬 ISLB Global Molecular Tumor Board: Breast Cancer
Thank you to everyone who joined today’s ISLB Global Molecular Tumor Board – Breast Cancer, part of the ISLB Education Series.
The interactive session explored the evolving role of liquid biopsy and ctDNA in breast cancer, on molecular residual disease (MRD) in early triple-negative breast cancer, ctDNA dynamics around neoadjuvant therapy and surgery, and the potential future role of molecular monitoring in treatment escalation and de-escalation.
A key discussion centered on an increasingly important question:
Can ctDNA move from predicting recurrence to actually guiding treatment decisions in early breast cancer?
Many thanks to our moderators Mark Basik and Adriana Aguilar, presenter Mark Basik, and invited panelists Cristiano Ferrario, @AlexandrePCheng , @jvburnier , and Parvaneh Fallah for an engaging and clinically relevant discussion.
On behalf of the ISLB Education Committee, coordinated by @BrunaPellini and @JordiRemon , thank you to our faculty and participants for making this another highly interactive Global MTB session.
🌍 Advancing molecular diagnostics through global discussion, education, and collaboration.
#ISLB #LiquidBiopsy #BreastCancer #ctDNA #MRD #TNBC #PrecisionOncology #MolecularTumorBoard
@UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez @PasqualePisapia @BenBleibergMD @Al3ssandroRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @LuisRaezMD @DrYukselUrun
Thank you to everyone who joined today’s ISLB Global Molecular Tumor Board – Breast Cancer, part of the ISLB Education Series.
The interactive session explored the evolving role of liquid biopsy and ctDNA in breast cancer, on molecular residual disease (MRD) in early triple-negative breast cancer, ctDNA dynamics around neoadjuvant therapy and surgery, and the potential future role of molecular monitoring in treatment escalation and de-escalation.
A key discussion centered on an increasingly important question:
Can ctDNA move from predicting recurrence to actually guiding treatment decisions in early breast cancer?
Many thanks to our moderators Mark Basik and Adriana Aguilar, presenter Mark Basik, and invited panelists Cristiano Ferrario, @AlexandrePCheng , @jvburnier , and Parvaneh Fallah for an engaging and clinically relevant discussion.
On behalf of the ISLB Education Committee, coordinated by @BrunaPellini and @JordiRemon , thank you to our faculty and participants for making this another highly interactive Global MTB session.
🌍 Advancing molecular diagnostics through global discussion, education, and collaboration.
#ISLB #LiquidBiopsy #BreastCancer #ctDNA #MRD #TNBC #PrecisionOncology #MolecularTumorBoard
@UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez @PasqualePisapia @BenBleibergMD @Al3ssandroRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @LuisRaezMD @DrYukselUrun
1
8
16
773
ELO retweeted
#ISLB2026 If you are working in liquid biopsy or you just want to learn about how it is evolving into so many standards of care, come join us in Madrid. Unique multidisciplinary stakeholder workshop is a highlight. Nothing like it in the world. @isliquidbiopsy @UmbertoMalapel1
🩸🧬Liquid biopsy is reshaping how we think about cancer biology, monitoring and precision treatment. Looking forward to ISLB 2026 in Madrid and the conversations ahead.
@isliquidbiopsy @UmbertoMalapel1 @ChristianRolfo @ElJanLe @drgandara
3
10
16
1,927
ELO retweeted
Durante hoy y mañana celebramos el I Precertorship en comités moleculares de tumores.
Una oportunidad para poner en valor los MTB y aprender juntos de nuestra práctica clínica diaria en un entorno verdaderamente multidisciplinar. 🧬🤝
@fihguv @HGUVALENCIA
Una oportunidad para poner en valor los MTB y aprender juntos de nuestra práctica clínica diaria en un entorno verdaderamente multidisciplinar. 🧬🤝
@fihguv @HGUVALENCIA
0
2
5
147
ELO retweeted
🩸🧬Liquid biopsy is reshaping how we think about cancer biology, monitoring and precision treatment. Looking forward to ISLB 2026 in Madrid and the conversations ahead.
@isliquidbiopsy @UmbertoMalapel1 @ChristianRolfo @ElJanLe @drgandara
@isliquidbiopsy @UmbertoMalapel1 @ChristianRolfo @ElJanLe @drgandara
One week left to secure the best registration rate for ISLB 2026!
Join leading researchers, clinicians and industry innovators in Madrid for the 8th Annual Congress of Liquid Biopsy, dedicated to advancing liquid biopsy science and clinical practice.
Register by 2 October 2026 rly Bird rates and secure your place.
𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗻𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿 → islb-congress.info
#ISLB2026 #LiquidBiopsy #PrecisionOncology #CancerResearch #Oncology #Congress
1
7
18
3,012
ELO retweeted
🌍 New @TheLancetOncol Commission: Making Precision Oncology More Equitable
Precision oncology is advancing rapidly but access to cancer genomics remains deeply unequal worldwide.
The new Lancet Oncology Commission reports that:
🧬 7–8 million patients with cancer require year
🌍 Millions still lack access to guideline-indicated biomarker testing
📊 Only 2% of biomarker-based trial–country activity analysed occurred in LMICs
🩸 Liquid biopsy is increasingly integrated into molecular profiling, MRD monitoring and resistance assessment
The message is clear: innovation alone is not enough.
Precision oncology must be implemented with evidence, quality, affordability, workforce capacity, reimbursement and equitable access at its core.
For the liquid biopsy community, this means moving beyond “Can we detect it?” toward:
“Can every eligible patient access testing, interpretation and an effective treatment?”
@DrYukselUrun @UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez @PasqualePisapia @Al3ssandroRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @LuisRaezMD
#PrecisionOncology #CancerGenomics #LiquidBiopsy #ctDNA #GlobalOncology #HealthEquity #CancerResearch #ISLB
Precision oncology is advancing rapidly but access to cancer genomics remains deeply unequal worldwide.
The new Lancet Oncology Commission reports that:
🧬 7–8 million patients with cancer require year
🌍 Millions still lack access to guideline-indicated biomarker testing
📊 Only 2% of biomarker-based trial–country activity analysed occurred in LMICs
🩸 Liquid biopsy is increasingly integrated into molecular profiling, MRD monitoring and resistance assessment
The message is clear: innovation alone is not enough.
Precision oncology must be implemented with evidence, quality, affordability, workforce capacity, reimbursement and equitable access at its core.
For the liquid biopsy community, this means moving beyond “Can we detect it?” toward:
“Can every eligible patient access testing, interpretation and an effective treatment?”
@DrYukselUrun @UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez @PasqualePisapia @Al3ssandroRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @LuisRaezMD
#PrecisionOncology #CancerGenomics #LiquidBiopsy #ctDNA #GlobalOncology #HealthEquity #CancerResearch #ISLB
0
13
19
940
